According to Wind data, as of March 24, over 70% of companies in the Shenwan pharmaceutical and biological industry that have disclosed their 2025 annual reports have achieved profitability, indicating a notable recovery trend. Comprehensive institutional research reports suggest that driven by factors such as earnings delivery, accelerated research and development, and sector undervaluation, the medium to long-term investment appeal of the pharmaceutical and biological sector, particularly in innovative drug segments, continues to gain prominence.
1. Annual Report Insights: Data Confirms Recovery in Pharmaceutical and Biological Sector Wind data shows that as of March 24, 169 companies in the A-share market's Shenwan pharmaceutical and biological industry have disclosed their 2025 annual reports. Among them, 121 companies reported positive net profits attributable to shareholders, accounting for over 70% of the total. Furthermore, 77 companies achieved year-on-year growth in net profit, with 20 companies posting growth rates exceeding 100%, highlighting both an overall profit recovery and structural differentiation within the sector. Analysts point out that March to April marks the earnings disclosure window for innovative drug companies, with many expected to report reduced losses or turn profitable. It is anticipated that more innovative drug firms will significantly release profits in 2026. With the approaching inflection point for profitability in the innovative drug sector, coupled with dense clinical data catalysts throughout the year and smooth progress in overseas clinical trials for partnered pipelines, institutions express optimism regarding opportunities in the innovative drug segment.
2. Accelerated R&D Innovation and Commercialization Since 2026, domestic pharmaceutical companies have continued to demonstrate strong momentum in research and development. Several A-share pharmaceutical firms have disclosed R&D progress announcements, reporting phased achievements in areas such as clinical trial approvals, marketing authorization application acceptances, and drug registration certificate approvals. These advancements span multiple therapeutic areas including anti-infectives, hyperlipidemia, pain management, inflammation, and autoimmune diseases. Analysis suggests that the successful commercialization of R&D achievements has a significant multiplier effect on improving companies' financial structures and may serve as a core driver for enhancing both performance quality and valuation reassessment. The primary value of commercializing R&D outcomes is reflected in direct revenue contributions, enabling rapid market monetization and continuous optimization of revenue structures. Institutions project that the pace of R&D achievement commercialization in the pharmaceutical industry during 2026 will likely follow a dual-track trend: acceleration for innovative drugs and quality improvement for generic drugs.
3. Ample Funding and Sustainable R&D Investment in Innovative Drug Sector Currently, business development (BD) revenue and post-IPO fundraising provide financial support for innovative drug companies' R&D efforts. According to Wind data, from January 1, 2024, to March 21, 2026, post-listing fundraising in the Hong Kong and A-share biopharmaceutical sectors totaled approximately 7 billion yuan, supporting R&D investments in innovative drug pipelines. Additionally, as of March 21, 2026, the total value of outbound BD deals for Chinese innovative drugs has reached $57.1 billion, making BD revenue a crucial funding source for these companies. Institutions note that the pharmaceutical sector currently enjoys ample liquidity, with most companies maintaining R&D funding coverage for over one year. This financial stability effectively supports subsequent clinical trial advancements, pipeline expansion, and technological innovation, laying a solid foundation for long-term, high-quality industry development and providing sufficient time windows for technological breakthroughs and commercialization in the innovative drug sector.
4. Attractive Risk-Reward Profile in Innovative Drug Sector Following a rally in 2025, the innovative drug sector has undergone a correction since the end of the third quarter of last year, lasting over six months, during which valuation risks have been largely mitigated. Over a longer timeframe, Wind data indicates that as of March 24, 2026, the current trailing price-to-earnings ratios (PE TTM) of the CSI Innovative Drug Industry Index and the CSI Hong Kong Innovative Drug Index stand at 40x and 41x, respectively, positioned at the 38.05% and 39.84% percentiles of their five-year ranges, suggesting an attractive risk-reward profile. For investors optimistic about the innovative drug sector but concerned about stock-specific volatility, considering index-based investment tools may represent a relatively efficient and transparent approach. Potential options include the Hong Kong Innovative Drug ETF (159567) and its feeder funds (Class A: 023929; Class C: 023930), as well as the Innovative Drug ETF (159992) and its feeder funds (Class A: 012781; Class C: 012782), aiming to capture the long-term growth benefits of the innovative drug industry.
Comments